tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Mani Foroohar, 175 are a BUY (56.27%), 108 are a HOLD (34.73%), 28 are a SELL (9%).
Analyst Mani Foroohar, currently employed at LEERINK, carries an average stock price target met ratio of 50.17% that have a potential upside of 43.84% achieved within 248 days.
Mani Foroohar’s has documented 598 price targets and ratings displayed on 35 stocks. The coverage is on Healthcare, Technology, Communication Services sectors.
Most recent stock forecast was given on NGNE, Neurogene at 01-Jul-2026.
Analyst best performing recommendations are on FDMT (4D MOLECULAR THERAPEUTICS).
The best stock recommendation documented was for FDMT (4D MOLECULAR THERAPEUTICS) at 11/14/2022. The price target of $15 was fulfilled within 1 day with a profit of $1.51 (11.19%) receiving and performance score of 111.93.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 30-Apr-2024
$5
$0.64 (14.68%)
11 months 2 days ago
(17-Nov-2025)
0/5 (0%)
$0.73 (17.10%)
Buy Since 01-Nov-2023
$5.5
$1.14 (26.15%)
$12
11 months 20 days ago
(29-Oct-2025)
1/7 (14.29%)
$1.27 (30.02%)
292
Hold Since 16-Apr-2025
$4
$-0.36 (-8.26%)
$5
11 months 21 days ago
(28-Oct-2025)
1/2 (50%)
$-0.26 (-6.10%)
168
Buy Since 18-Jul-2024
1 years 2 months 6 days ago
(13-Aug-2025)
2/3 (66.67%)
$30.52 (321.94%)
1046
Hold Since 19-Mar-2024
$4
$-0.36 (-8.26%)
$5
1 years 5 months 4 days ago
(15-May-2025)
4/6 (66.67%)
$1.95 (95.12%)
205
Which stock is Mani Foroohar most bullish on?
Which stock is Mani Foroohar most reserved on?
What Year was the first public recommendation made by Mani Foroohar?
